targetId
stringlengths 15
15
| diseaseId
stringlengths 9
15
| nctid
stringlengths 11
11
⌀ | clinicalStatus
stringclasses 9
values | clinicalPhase
int64 0
4
| studyStartDate
stringlengths 10
10
⌀ | stopStatus
stringclasses 3
values | isStopped
stringclasses 1
value | phase4
stringclasses 1
value | phase3
stringclasses 1
value | phase2
stringclasses 1
value | id
int64 0
1,709B
| why_stopped
stringlengths 2
254
⌀ | phase
stringclasses 7
values | start_date
stringlengths 10
10
⌀ | status
stringclasses 3
values | last_update_posted_date
stringlengths 10
10
⌀ | completion_date
stringlengths 10
10
⌀ | prediction
stringclasses 15
values | metaprediction
stringclasses 6
values | max_l2g
float64 0.05
0.9
⌀ | l2g_075
stringclasses 1
value | l2g_05
stringclasses 1
value | l2g_025
stringclasses 1
value | l2g_01
stringclasses 1
value | l2g_005
stringclasses 1
value | taId
stringclasses 23
values | taLabel
stringclasses 24
values | taLabelSimple
stringclasses 2
values | gc
float64 0
5
⌀ | lof_tolerance
stringclasses 2
values | rnaDistribution
stringclasses 5
values | rnaSpecificity
stringclasses 5
values | partnersBin
stringclasses 4
values | datasourceId
stringclasses 22
values | datatypeId
stringclasses 7
values | total
int64 413k
413k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ENSG00000004468
|
EFO_0000203
|
NCT03236428
|
Active, not recruiting
| 2 |
2017-11-24
| null | null | null | null |
Phase II+
| 1,082,331,760,593 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0005803
|
hematologic disease
|
Other
| 3 |
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
none
|
chembl
|
known_drug
| 413,311 |
ENSG00000004468
|
EFO_0000203
|
NCT03236428
|
Active, not recruiting
| 2 |
2017-11-24
| null | null | null | null |
Phase II+
| 1,082,331,760,593 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0005803
|
hematologic disease
|
Other
| 3 |
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
none
|
europepmc
|
literature
| 413,311 |
ENSG00000004468
|
EFO_0000203
|
NCT03236428
|
Active, not recruiting
| 2 |
2017-11-24
| null | null | null | null |
Phase II+
| 1,082,331,760,593 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0005803
|
hematologic disease
|
Other
| null |
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
none
|
chembl
|
known_drug
| 413,311 |
ENSG00000004468
|
EFO_0000203
|
NCT03236428
|
Active, not recruiting
| 2 |
2017-11-24
| null | null | null | null |
Phase II+
| 1,082,331,760,593 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0005803
|
hematologic disease
|
Other
| null |
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
none
|
europepmc
|
literature
| 413,311 |
ENSG00000004468
|
EFO_0000203
|
NCT03236428
|
Active, not recruiting
| 2 |
2017-11-24
| null | null | null | null |
Phase II+
| 1,082,331,760,593 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0005803
|
hematologic disease
|
Other
| null |
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
none
|
chembl
|
known_drug
| 413,311 |
ENSG00000004468
|
EFO_0000203
|
NCT03236428
|
Active, not recruiting
| 2 |
2017-11-24
| null | null | null | null |
Phase II+
| 1,082,331,760,593 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0005803
|
hematologic disease
|
Other
| null |
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
none
|
europepmc
|
literature
| 413,311 |
ENSG00000004468
|
EFO_0000203
|
NCT04614558
|
Recruiting
| 2 |
2021-06-08
| null | null | null | null |
Phase II+
| 1,065,151,891,406 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0005803
|
hematologic disease
|
Other
| 3 |
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
none
|
chembl
|
known_drug
| 413,311 |
ENSG00000004468
|
EFO_0000203
|
NCT04614558
|
Recruiting
| 2 |
2021-06-08
| null | null | null | null |
Phase II+
| 1,065,151,891,406 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0005803
|
hematologic disease
|
Other
| 3 |
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
none
|
europepmc
|
literature
| 413,311 |
ENSG00000004468
|
EFO_0000203
|
NCT04614558
|
Recruiting
| 2 |
2021-06-08
| null | null | null | null |
Phase II+
| 1,065,151,891,406 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0005803
|
hematologic disease
|
Other
| null |
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
none
|
chembl
|
known_drug
| 413,311 |
ENSG00000004468
|
EFO_0000203
|
NCT04614558
|
Recruiting
| 2 |
2021-06-08
| null | null | null | null |
Phase II+
| 1,065,151,891,406 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0005803
|
hematologic disease
|
Other
| null |
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
none
|
europepmc
|
literature
| 413,311 |
ENSG00000004468
|
EFO_0000203
|
NCT04614558
|
Recruiting
| 2 |
2021-06-08
| null | null | null | null |
Phase II+
| 1,065,151,891,406 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0005803
|
hematologic disease
|
Other
| null |
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
none
|
chembl
|
known_drug
| 413,311 |
ENSG00000004468
|
EFO_0000203
|
NCT04614558
|
Recruiting
| 2 |
2021-06-08
| null | null | null | null |
Phase II+
| 1,065,151,891,406 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0005803
|
hematologic disease
|
Other
| null |
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
none
|
europepmc
|
literature
| 413,311 |
ENSG00000004779
|
EFO_1001249
|
NCT00699036
|
Unknown status
| 2 |
2007-04-01
| null | null | null | null |
Phase II+
| 120,259,084,622 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0010282
|
gastrointestinal disease
|
Other
| 2 | null |
Detected in all
|
Tissue enhanced
|
greaterThan20
|
chembl
|
known_drug
| 413,311 |
ENSG00000004779
|
EFO_1001249
|
NCT00699036
|
Unknown status
| 2 |
2007-04-01
| null | null | null | null |
Phase II+
| 120,259,084,622 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0010282
|
gastrointestinal disease
|
Other
| null | null |
Detected in all
|
Tissue enhanced
|
greaterThan20
|
chembl
|
known_drug
| 413,311 |
ENSG00000004779
|
EFO_1001249
|
NCT00699036
|
Unknown status
| 2 |
2007-04-01
| null | null | null | null |
Phase II+
| 120,259,084,622 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0010282
|
gastrointestinal disease
|
Other
| null | null |
Detected in all
|
Tissue enhanced
|
greaterThan20
|
chembl
|
known_drug
| 413,311 |
ENSG00000004779
|
EFO_1001249
|
NCT04972396
|
Recruiting
| 1 |
2021-10-05
| null | null | null | null | null | 343,597,383,747 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0010282
|
gastrointestinal disease
|
Other
| 2 | null |
Detected in all
|
Tissue enhanced
|
greaterThan20
|
chembl
|
known_drug
| 413,311 |
ENSG00000004779
|
EFO_1001249
|
NCT04972396
|
Recruiting
| 1 |
2021-10-05
| null | null | null | null | null | 343,597,383,747 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0010282
|
gastrointestinal disease
|
Other
| null | null |
Detected in all
|
Tissue enhanced
|
greaterThan20
|
chembl
|
known_drug
| 413,311 |
ENSG00000004779
|
EFO_1001249
|
NCT04972396
|
Recruiting
| 1 |
2021-10-05
| null | null | null | null | null | 343,597,383,747 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0010282
|
gastrointestinal disease
|
Other
| null | null |
Detected in all
|
Tissue enhanced
|
greaterThan20
|
chembl
|
known_drug
| 413,311 |
ENSG00000011677
|
EFO_0003768
|
NCT02406066
|
Completed
| 1 |
2015-03-01
| null | null | null | null | null | 824,633,722,293 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| 2 |
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311 |
ENSG00000011677
|
EFO_0003768
|
NCT02406066
|
Completed
| 1 |
2015-03-01
| null | null | null | null | null | 824,633,722,293 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| null |
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311 |
ENSG00000011677
|
EFO_0003768
|
NCT02406066
|
Completed
| 1 |
2015-03-01
| null | null | null | null | null | 824,633,722,293 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| null |
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311 |
ENSG00000011677
|
EFO_0003768
|
NCT00802412
|
Completed
| 2 |
2009-01-01
| null | null | null | null |
Phase II+
| 893,353,198,669 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| 2 |
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311 |
ENSG00000011677
|
EFO_0003768
|
NCT00802412
|
Completed
| 2 |
2009-01-01
| null | null | null | null |
Phase II+
| 893,353,198,669 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| null |
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311 |
ENSG00000011677
|
EFO_0003768
|
NCT00802412
|
Completed
| 2 |
2009-01-01
| null | null | null | null |
Phase II+
| 893,353,198,669 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| null |
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311 |
ENSG00000011677
|
EFO_0003768
|
NCT00208858
|
Completed
| 2 |
2004-12-01
| null | null | null | null |
Phase II+
| 1,185,410,975,178 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| 2 |
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311 |
ENSG00000011677
|
EFO_0003768
|
NCT00208858
|
Completed
| 2 |
2004-12-01
| null | null | null | null |
Phase II+
| 1,185,410,975,178 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| null |
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311 |
ENSG00000011677
|
EFO_0003768
|
NCT00208858
|
Completed
| 2 |
2004-12-01
| null | null | null | null |
Phase II+
| 1,185,410,975,178 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| null |
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311 |
ENSG00000011677
|
EFO_0003768
|
NCT03813121
|
Completed
| 1 |
2019-06-01
| null | null | null | null | null | 1,365,799,601,280 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| 2 |
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311 |
ENSG00000011677
|
EFO_0003768
|
NCT03813121
|
Completed
| 1 |
2019-06-01
| null | null | null | null | null | 1,365,799,601,280 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| null |
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311 |
ENSG00000011677
|
EFO_0003768
|
NCT03813121
|
Completed
| 1 |
2019-06-01
| null | null | null | null | null | 1,365,799,601,280 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| null |
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311 |
ENSG00000011677
|
EFO_0003768
|
NCT01182766
|
Active, not recruiting
| 2 |
2011-09-01
| null | null | null | null |
Phase II+
| 1,374,389,536,597 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| 2 |
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311 |
ENSG00000011677
|
EFO_0003768
|
NCT01182766
|
Active, not recruiting
| 2 |
2011-09-01
| null | null | null | null |
Phase II+
| 1,374,389,536,597 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| null |
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311 |
ENSG00000011677
|
EFO_0003768
|
NCT01182766
|
Active, not recruiting
| 2 |
2011-09-01
| null | null | null | null |
Phase II+
| 1,374,389,536,597 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| null |
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311 |
ENSG00000011677
|
EFO_0003768
|
NCT00755716
|
Completed
| 3 |
2006-04-01
| null | null | null |
Phase III+
|
Phase II+
| 1,382,979,470,922 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| 2 |
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311 |
ENSG00000011677
|
EFO_0003768
|
NCT00755716
|
Completed
| 3 |
2006-04-01
| null | null | null |
Phase III+
|
Phase II+
| 1,382,979,470,922 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| null |
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311 |
ENSG00000011677
|
EFO_0003768
|
NCT00755716
|
Completed
| 3 |
2006-04-01
| null | null | null |
Phase III+
|
Phase II+
| 1,382,979,470,922 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
EFO_0000618
|
nervous system disease
|
Other
| null |
LoF tolerant
|
Detected in some
|
Group enriched
|
none
|
chembl
|
known_drug
| 413,311 |
ENSG00000012779
|
EFO_0002609
| null | null | 4 | null | null | null |
Phase IV
|
Phase III+
|
Phase II+
| 1,597,727,834,458 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
OTAR_0000006
|
musculoskeletal or connective tissue disease
|
Other
| 1 |
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
greaterThan20
|
chembl
|
known_drug
| 413,311 |
ENSG00000012779
|
EFO_0002609
| null | null | 4 | null | null | null |
Phase IV
|
Phase III+
|
Phase II+
| 1,597,727,834,458 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
OTAR_0000006
|
musculoskeletal or connective tissue disease
|
Other
| null |
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
greaterThan20
|
chembl
|
known_drug
| 413,311 |
ENSG00000012779
|
EFO_0002609
| null | null | 4 | null | null | null |
Phase IV
|
Phase III+
|
Phase II+
| 1,597,727,834,458 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
OTAR_0000006
|
musculoskeletal or connective tissue disease
|
Other
| null |
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
greaterThan20
|
chembl
|
known_drug
| 413,311 |
ENSG00000012779
|
EFO_0002609
|
NCT00637780
|
Terminated
| 4 |
2010-06-01
|
Terminated
|
stopped
|
Phase IV
|
Phase III+
|
Phase II+
| 618,475,292,173 |
Study terminated on 13 April 2016 for business reasons. No safety and/or efficacy concerns contributed to the termination of the study
|
Phase 4
|
30/06/2010
|
Terminated
|
23/02/2017
|
31/01/2014
|
Business_Administrative
|
Business_Administrative
| null | null | null | null | null | null |
OTAR_0000006
|
musculoskeletal or connective tissue disease
|
Other
| 1 |
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
greaterThan20
|
chembl
|
known_drug
| 413,311 |
ENSG00000012779
|
EFO_0002609
|
NCT00637780
|
Terminated
| 4 |
2010-06-01
|
Terminated
|
stopped
|
Phase IV
|
Phase III+
|
Phase II+
| 618,475,292,173 |
Study terminated on 13 April 2016 for business reasons. No safety and/or efficacy concerns contributed to the termination of the study
|
Phase 4
|
30/06/2010
|
Terminated
|
23/02/2017
|
31/01/2014
|
Business_Administrative
|
Business_Administrative
| null | null | null | null | null | null |
OTAR_0000006
|
musculoskeletal or connective tissue disease
|
Other
| null |
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
greaterThan20
|
chembl
|
known_drug
| 413,311 |
ENSG00000012779
|
EFO_0002609
|
NCT00637780
|
Terminated
| 4 |
2010-06-01
|
Terminated
|
stopped
|
Phase IV
|
Phase III+
|
Phase II+
| 618,475,292,173 |
Study terminated on 13 April 2016 for business reasons. No safety and/or efficacy concerns contributed to the termination of the study
|
Phase 4
|
30/06/2010
|
Terminated
|
23/02/2017
|
31/01/2014
|
Business_Administrative
|
Business_Administrative
| null | null | null | null | null | null |
OTAR_0000006
|
musculoskeletal or connective tissue disease
|
Other
| null |
LoF tolerant
|
Detected in many
|
Tissue enhanced
|
greaterThan20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
EFO_1002001
|
NCT01238211
|
Active, not recruiting
| 2 |
2010-12-14
| null | null | null | null |
Phase II+
| 523,986,011,570 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
EFO_1002001
|
NCT01238211
|
Active, not recruiting
| 2 |
2010-12-14
| null | null | null | null |
Phase II+
| 523,986,011,570 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
EFO_1002001
|
NCT01238211
|
Active, not recruiting
| 2 |
2010-12-14
| null | null | null | null |
Phase II+
| 523,986,011,570 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT00003204
|
Completed
| 3 |
1998-03-01
| null | null | null |
Phase III+
|
Phase II+
| 292,057,776,621 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT00003204
|
Completed
| 3 |
1998-03-01
| null | null | null |
Phase III+
|
Phase II+
| 292,057,776,621 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT00003204
|
Completed
| 3 |
1998-03-01
| null | null | null |
Phase III+
|
Phase II+
| 292,057,776,621 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT00510887
|
Terminated
| 2 |
2007-01-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 352,187,319,161 |
Low accrual.
|
Phase 2
|
31/01/2007
|
Terminated
|
12/05/2014
|
30/09/2013
|
Insufficient_Enrollment
|
Neutral
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT00510887
|
Terminated
| 2 |
2007-01-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 352,187,319,161 |
Low accrual.
|
Phase 2
|
31/01/2007
|
Terminated
|
12/05/2014
|
30/09/2013
|
Insufficient_Enrollment
|
Neutral
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT00510887
|
Terminated
| 2 |
2007-01-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 352,187,319,161 |
Low accrual.
|
Phase 2
|
31/01/2007
|
Terminated
|
12/05/2014
|
30/09/2013
|
Insufficient_Enrollment
|
Neutral
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT02348216
|
Active, not recruiting
| 1 |
2015-04-21
| null | null | null | null | null | 377,957,122,485 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT02348216
|
Active, not recruiting
| 1 |
2015-04-21
| null | null | null | null | null | 377,957,122,485 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT02348216
|
Active, not recruiting
| 1 |
2015-04-21
| null | null | null | null | null | 377,957,122,485 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT00169208
|
Completed
| 2 |
2001-04-01
| null | null | null | null |
Phase II+
| 609,885,357,182 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT00169208
|
Completed
| 2 |
2001-04-01
| null | null | null | null |
Phase II+
| 609,885,357,182 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT00169208
|
Completed
| 2 |
2001-04-01
| null | null | null | null |
Phase II+
| 609,885,357,182 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT00924326
|
Completed
| 1 |
2009-02-17
| null | null | null | null | null | 755,914,245,467 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT00924326
|
Completed
| 1 |
2009-02-17
| null | null | null | null | null | 755,914,245,467 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT00924326
|
Completed
| 1 |
2009-02-17
| null | null | null | null | null | 755,914,245,467 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT01321541
|
Completed
| 3 |
2011-04-20
| null | null | null |
Phase III+
|
Phase II+
| 876,173,329,055 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT01321541
|
Completed
| 3 |
2011-04-20
| null | null | null |
Phase III+
|
Phase II+
| 876,173,329,055 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT01321541
|
Completed
| 3 |
2011-04-20
| null | null | null |
Phase III+
|
Phase II+
| 876,173,329,055 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT02295722
|
Unknown status
| 1 |
2015-04-01
| null | null | null | null | null | 42,949,674,404 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT02295722
|
Unknown status
| 1 |
2015-04-01
| null | null | null | null | null | 42,949,674,404 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT02295722
|
Unknown status
| 1 |
2015-04-01
| null | null | null | null | null | 42,949,674,404 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT00110071
|
Completed
| 1 |
2005-01-01
| null | null | null | null | null | 77,309,411,723 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT00110071
|
Completed
| 1 |
2005-01-01
| null | null | null | null | null | 77,309,411,723 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT00110071
|
Completed
| 1 |
2005-01-01
| null | null | null | null | null | 77,309,411,723 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT00119392
|
Completed
| 2 |
2004-06-01
| null | null | null | null |
Phase II+
| 240,518,169,289 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT00119392
|
Completed
| 2 |
2004-06-01
| null | null | null | null |
Phase II+
| 240,518,169,289 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT00119392
|
Completed
| 2 |
2004-06-01
| null | null | null | null |
Phase II+
| 240,518,169,289 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT01529827
|
Completed
| 2 |
2012-02-28
| null | null | null | null |
Phase II+
| 317,827,580,785 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT01529827
|
Completed
| 2 |
2012-02-28
| null | null | null | null |
Phase II+
| 317,827,580,785 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT01529827
|
Completed
| 2 |
2012-02-28
| null | null | null | null |
Phase II+
| 317,827,580,785 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT00562965
|
Terminated
| 3 |
2007-11-01
|
Terminated
|
stopped
| null |
Phase III+
|
Phase II+
| 369,367,188,591 |
See termination reason in detailed description.
|
Phase 3
|
30/11/2007
|
Terminated
|
09/01/2018
|
30/04/2011
|
No_Context
|
Neutral
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT00562965
|
Terminated
| 3 |
2007-11-01
|
Terminated
|
stopped
| null |
Phase III+
|
Phase II+
| 369,367,188,591 |
See termination reason in detailed description.
|
Phase 3
|
30/11/2007
|
Terminated
|
09/01/2018
|
30/04/2011
|
No_Context
|
Neutral
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT00562965
|
Terminated
| 3 |
2007-11-01
|
Terminated
|
stopped
| null |
Phase III+
|
Phase II+
| 369,367,188,591 |
See termination reason in detailed description.
|
Phase 3
|
30/11/2007
|
Terminated
|
09/01/2018
|
30/04/2011
|
No_Context
|
Neutral
| null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT00079443
|
Terminated
| 2 |
2004-01-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 412,316,861,764 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT00079443
|
Terminated
| 2 |
2004-01-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 412,316,861,764 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT00079443
|
Terminated
| 2 |
2004-01-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 412,316,861,764 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT01303887
|
Unknown status
| 3 |
2009-10-01
| null | null | null |
Phase III+
|
Phase II+
| 601,295,421,934 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT01303887
|
Unknown status
| 3 |
2009-10-01
| null | null | null |
Phase III+
|
Phase II+
| 601,295,421,934 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT01303887
|
Unknown status
| 3 |
2009-10-01
| null | null | null |
Phase III+
|
Phase II+
| 601,295,421,934 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT00393107
|
Completed
| 2 |
2000-03-01
| null | null | null | null |
Phase II+
| 953,482,741,355 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT00393107
|
Completed
| 2 |
2000-03-01
| null | null | null | null |
Phase II+
| 953,482,741,355 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT00393107
|
Completed
| 2 |
2000-03-01
| null | null | null | null |
Phase II+
| 953,482,741,355 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT03019640
|
Completed
| 2 |
2017-10-10
| null | null | null | null |
Phase II+
| 970,662,610,863 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT03019640
|
Completed
| 2 |
2017-10-10
| null | null | null | null |
Phase II+
| 970,662,610,863 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT03019640
|
Completed
| 2 |
2017-10-10
| null | null | null | null |
Phase II+
| 970,662,610,863 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT00140569
|
Completed
| 3 |
1994-01-01
| null | null | null |
Phase III+
|
Phase II+
| 1,099,511,629,558 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT00140569
|
Completed
| 3 |
1994-01-01
| null | null | null |
Phase III+
|
Phase II+
| 1,099,511,629,558 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT00140569
|
Completed
| 3 |
1994-01-01
| null | null | null |
Phase III+
|
Phase II+
| 1,099,511,629,558 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT03128359
|
Active, not recruiting
| 2 |
2017-05-30
| null | null | null | null |
Phase II+
| 1,357,209,666,455 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT03128359
|
Active, not recruiting
| 2 |
2017-05-30
| null | null | null | null |
Phase II+
| 1,357,209,666,455 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT03128359
|
Active, not recruiting
| 2 |
2017-05-30
| null | null | null | null |
Phase II+
| 1,357,209,666,455 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT00850499
|
Terminated
| 2 |
2009-09-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 1,425,929,143,471 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT00850499
|
Terminated
| 2 |
2009-09-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 1,425,929,143,471 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT00850499
|
Terminated
| 2 |
2009-09-01
|
Terminated
|
stopped
| null | null |
Phase II+
| 1,425,929,143,471 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| null |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
ENSG00000014138
|
MONDO_0018906
|
NCT03105336
|
Active, not recruiting
| 2 |
2017-06-20
| null | null | null | null |
Phase II+
| 1,606,317,770,278 | null | null | null | null | null | null | null | null | null | null | null | null | null | null |
MONDO_0045024
|
cell proliferation disorder
|
Oncology
| 2 |
LoF tolerant
|
Detected in all
|
Low tissue specificity
|
from11to20
|
chembl
|
known_drug
| 413,311 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.